High-throughput assay identifies small molecule ligands for RNA structures, suggesting new screening methods for drug discovery.
There is an indisputable need for new screening methodologies to identify small molecules that target RNA tertiary structures, such as pseudoknots or G-quadruplexes. Here, we present a high-throughput competitive binding antisense assay designed to identify ligands for complex RNA tertiary structures. In this assay, initially customized for the bacterial PreQ1-I riboswitch pseudoknot, ligands compete with a rationally designed quencher-labelled antisense oligonucleotide for binding to a fluorophore-labelled riboswitch. The method is validated for four PreQ1-I riboswitches, using the natural riboswitch ligand PreQ1 and various analogues. A commercial RNA-focused library consisting of ∼15 000 compounds was then screened against the Fusobacterium nucleatum riboswitch, leading to the identification of a promising hit, 4494, which showed competitive binding activity to all PreQ1-I riboswitches and was able to inhibit translation of a riboswitch-regulated reporter gene. Although resynthesis of 4494 revealed that its activity originated from an ∼1% guanine contamination, this result underscores the assay's exceptional sensitivity. To demonstrate its versatility, the assay was tailored for a SARS-CoV-2 G-quadruplex structure and validated with several known G-quadruplex ligands. This work shows that the competitive binding antisense assay is a powerful addition to the RNA-targeting toolbox, facilitating the discovery of ligands for diverse RNA tertiary structures.
No takes yet. Share an insight, caveat, or question.
Wintermans et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: